Loading…
Loading…
EQUITY / NASDAQ · XNCM
Estrella Immunopharma, Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗0.4667 USD
Observed: 09/30/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
09/30/2026 · 0.4667 USD · Volume 18,384
251 actual observations · Latest bar: 2026-09-30 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Operating profit | -2,084,247 USD | -5,544,028 USD | — |
| Net income | -2,306,339 USD | -5,544,878 USD | — |
| Cash and cash equivalents | 100,000 USD | — | — |
| Total liabilities | 9,256,014 USD | — | — |
| Total equity | -7,431,333 USD | -6,094,668 USD | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 100,000 USD | — | — | — | 1,384,302 USD | 1,626,610 USD | — | — |
| Net incomeIncome statement | -2,306,339 USD | -4,598,403 USD | -2,292,064 USD | — | -13,063,512 USD | -4,801,149 USD | -12,450,338 USD | -5,544,878 USD |
| Operating profitIncome statement | -2,084,247 USD | -4,267,684 USD | — | — | -13,062,674 USD | -4,801,149 USD | -12,449,475 USD | -5,544,028 USD |
| Total assetsBalance sheet | 1,824,681 USD | — | — | 3,176,975 USD | 3,176,975 USD | 3,523,511 USD | — | — |
| Total equityBalance sheet | -7,431,333 USD | — | -5,270,296 USD | -10,366,058 USD | -10,366,058 USD | -9,836,423 USD | — | -6,094,668 USD |
| Total liabilitiesBalance sheet | 9,256,014 USD | — | — | 13,543,033 USD | 13,543,033 USD | 13,359,934 USD | — | — |
| Financing cash flowCash flow statement | — | 7,241,116 USD | — | — | 2,253,065 USD | — | 2,317,886 USD | — |
| Operating cash flowCash flow statement | — | -8,478,748 USD | — | — | -1,785,679 USD | — | -1,608,192 USD | — |
| Report source | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 03/18/2026 | Open report ↗ Published: 11/12/2025 | Open report ↗ Published: 11/12/2025 | Open report ↗ Published: 08/13/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.